Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
about
Glucagon and heart in type 2 diabetes: new perspectivesCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular safety of anti-diabetic drugsCurrent perspectives on cardiovascular outcome trials in diabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsUpdate on the treatment of type 2 diabetes mellitusClinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus ManagementPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.The regulatory role of DPP4 in atherosclerotic disease.DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.Puerarin Improves Diabetic Aorta Injury by Inhibiting NADPH Oxidase-Derived Oxidative Stress in STZ-Induced Diabetic RatsClinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsCardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.An overview of new GLP-1 receptor agonists for type 2 diabetes.Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.Cardiometabolic crosstalk in obesity-associated arterial hypertension.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Implications of the EMPA-REG Trial for Clinical Care and Research.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.Cardiovascular effects of anti-diabetes drugs.Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.Progressing From Metformin to Sulfonylureas or Meglitinides.Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.Coronary microvascular dysfunction in diabetes mellitus.Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus.Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.
P2860
Q26738580-8381DC8F-985E-4433-877D-62AE4E798A3BQ26740253-838BA258-D7F9-435C-A46E-E79A392FA5A3Q26741082-72FA29D2-38CC-41C2-BCD1-AB6FA6B6399FQ28066006-D2D34A7A-2910-41F2-ABD8-0A12BD85DC6BQ28072765-266061A8-97AE-4901-9B3E-60C3E6EC739FQ28073342-4872BF78-09F5-4E91-A01A-0CA39FC4DA2EQ30238519-2E763A12-C5FB-4348-A4DB-0E676346A5B3Q30249371-F55D4150-23A9-4A01-BA51-0339F1FECBF9Q33625568-3BA0F957-051E-4E87-9FAC-514919F04A50Q33696974-D6E1653C-9EE2-4773-A1A6-838355EF203CQ33700894-C2485250-4A58-4C99-B892-E17532790F09Q33727891-CCC76FF6-BCB2-48A4-916B-7593D7D00BFBQ33732583-2B1525CA-C0C7-4798-AD72-6B1D1D42DDF5Q33805518-EAB9D244-1F55-4BAD-AF28-DCE20B61E950Q36338382-9380A84D-9C64-433E-9A6F-C3C9F665FBD4Q36531636-5CADC856-22D4-4F11-8383-76793398930FQ37011769-44AB6528-8E71-4C87-BC33-879E1936E3BAQ37620904-80E277CB-C6EA-4C48-BA2F-B129EF4D50F9Q38599145-8626855D-5E07-4D65-968E-883350CEA765Q38639922-8CB35F59-6BB2-4452-AC11-94AF49460F11Q38662950-6DA901FC-A65B-4CCD-AB2C-5D234EB0FFDEQ38683079-7A8E9919-A15D-4BB6-B675-4497A251E9BCQ38702260-EEE75132-0347-4F80-B548-5FB1C716E5DFQ38767511-3D8C4EAF-F2F0-442D-B578-B2BCFCD1F6F7Q38783203-4497BE0D-A961-4698-A6CB-6DB52320200AQ38798623-1D3BB769-B4A1-4E2E-910F-A8E1C999EDA1Q38827756-FF98B493-F7D6-44FA-9122-0049EB8286B7Q38857056-739E3E85-A818-47A8-95D6-E1929E958739Q38877104-DB8B8254-7D8B-47F9-A02A-42822848CAAFQ38937735-58F4C6A9-D9DF-4D02-BC9A-6BCE7EDA4A7CQ38952882-B8B22253-638D-4D73-B10A-BC44D3A2CC1EQ39226058-A5F0A221-B431-4F1A-BE4C-BA9F3E3EF590Q39245449-F33A2646-8682-4C9E-9A5A-0BE451A92025Q39393549-1BFD7114-DC47-4F50-93BB-53F581079133Q39409421-F661E873-8DAC-401D-943D-8B3A987ED9E3Q39418202-EB973F6D-F637-4685-9863-AFB9CD43BB81Q39735496-1FAD56B7-B8DC-4453-A52D-C0949D22DD59Q40113914-806279AC-ABF6-4764-B5B9-34E78FF28648Q40808660-FCC59763-D691-4CE8-B705-EF5E59DB11F0Q46078298-E562B5DC-642D-4A17-9AB8-16AD5C3CCF3D
P2860
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
@en
type
label
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
@en
prefLabel
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
@en
P2860
P356
P1476
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
@en
P2093
Ele Ferrannini
P2860
P304
P356
10.1093/EURHEARTJ/EHV239
P577
2015-06-10T00:00:00Z